PHAT earnings analysis
What we found in PHAT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Phathom Pharmaceuticals (PHAT) reported Q1 2026 revenues of $58.3 million, significantly exceeding expectations and marking substantial year-over-year growth of 104%. While EPS stood at -$0.37, missing the analyst projection of -$0.21, management remains optimistic about reaching profitability beginning in Q3 2026 amidst efforts to enhance commercial execution.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Exceeds Estimates
- Q1 2026 revenues reached $58.3 million, surpassing estimates of $56.8 million, reflecting a 104% increase from $28.5 million in Q1 2025.
- Reduction in Operating Loss
- Operating loss decreased significantly to $15.5 million from $78.9 million in the prior year.
- Decreased R&D Expenses
- Research and development expenses fell to $7.8 million from $9.2 million, indicating improved operational efficiency.
- Improved Gross Margin
- Gross profit increased to $46.3 million, with gross margin at approximately 79.4% for Q1 2026.
- Cash Position Stabilized
- As of March 31, 2026, the company held cash and cash equivalents of $180.9 million.
- Progress in Prescriber Adoption
- Since the launch, approximately 1.35 million prescriptions for VOQUEZNA products have been filled as of April 17, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Burn Rate
- Net losses for Q1 2026 were $30.4 million, showing ongoing challenges in achieving break-even.
- Potential Need for Additional Financing
- The company may need additional capital sooner than expected due to unpredictable operational cash needs.
- Regulatory and Market Competition Risks
- Concerns around ongoing regulatory changes and increasing competition in the biopharmaceutical space impact market positioning.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.37
- Gross margin
- 79.4%
What they said about what is next.
Management maintains FY 2026 revenue guidance of $320-$345 million and anticipates achieving profitability starting Q3 2026.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Phathom (PHAT) shows strong commercial traction for VOQUEZNA with continuing revenue ramp and improving losses. Q4 2025 revenue was $57,584,000 with GAAP EPS of $(0.08); gross margin remains high (~86.7% in 2025Q4)…
- 10-Q · August 7, 2025
- Phathom reported Q2 product revenue of $39,503,000, up from $7,324,000 in Q2 2024, driving gross profit of $34,465,000 (≈87% margin). Losses narrowed versus last year: loss from operations improved to $(59,924,000) from…
- 10-Q · May 1, 2025
- Phathom reported Q1 2025 product revenue of $28,519,000 (up from $1,912,000 in Q1 2024 and slightly below the prior-quarter ~$30M), achieving an 86.9% gross margin but registering a larger GAAP net loss of $94,316,000…
- 10-K · March 6, 2025
- Phathom’s 10-K emphasizes commercialization of VOQUEZNA (vonoprazan) as the core strategy, supported by recent FDA approvals (including July 17, 2024 approval of VOQUEZNA 10 mg for Non-Erosive GERD) and plans to expand…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PHAT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever